Application | Comment | Organism |
---|---|---|
medicine | in clinical samples, a worse outcome is associated with increased levels of dihydrofolate reductase and C-MYC at diagnosis in osteosarcoma patients treated with a methotrexate-based protocol and of C-MYC in patients treated with a standard four-drug regimen. The assessment of C-MYC and dihydrolfolate reductase at diagnosis, together with that of other known prognostic markers, can be considered for an early identification of subgroups of OS patients with higher risk of adverse outcome | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
patients with osteosarcoma | - |